Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

In gastric cancer, Keytruda is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic ...

“Whereas in Malaysia, screening is still primarily focused on individuals with gastric issues, a strong family history of cancer, or those exhibiting warning symptoms for cancer such as difficulty ...